Mary Thistle

Ms. Mary T.
Thistle, CPA, is an Independent Director at Aktis Oncology, Inc., an Independent Director at Cullinan Therapeutics, Inc., an Independent Director at Entrada Therapeutics, Inc., an Independent Director at Q32 Bio, Inc. and an Independent Director at Enterome SA. She is on the Board of Directors at Aktis Oncology, Inc., Cullinan Therapeutics, Inc., Entrada Therapeutics, Inc., Q32 Bio, Inc., Cocoon Biotech, Inc. and Enterome SA. Ms. Thistle was previously employed as an Independent Director by Vigil Neuroscience, Inc., an Independent Director by Alaunos Therapeutics, Inc., an Independent Director by Homology Medicines, Inc., a Chief of Staff by Bill & Melinda Gates Medical Research Institute, a Chief Financial & Accounting Officer by Dimension Therapeutics, Inc., a Senior Vice President-Business Development by Cubist Pharmaceuticals, Inc., a Senior Vice President-Business Development by PerkinElmer U.S.
LLC, a Senior Vice President-Business Development by ViaCell, Inc., an Accountant by Deloitte & Touche LLP, a Principal by Sierra Research & Technology, Inc., and a Consultant by Yoshida & Sokolski PC.
She received her undergraduate degree from the University of Massachusetts.